We recently published a list of 10 Firms Defy Market Slump, Record Double-Digit Gains Last Week. In this article, we are ...

Summit Therapeutics' ivonescimab shows potential in cancer treatment, but high risks and valuation concerns suggest caution.

We recently published a list of Gold, Biopharma Firms Dominate Friday’s 10 Top Performing Stocks. In this article, we are ...

We recently published a list of 10 Firms Buck Thursday’s Market Bloodbath. In this article, we are going to take a look at ...

The UK's new car market experienced a 12.4% increase in March 2025, reaching 357,103 units, according to the Society of Motor ...

Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Summit Therapeutics (SMMT – Research Report) today. The company’s ...

Summit Therapeutics Inc.’s SMMT share price has surged by 10.04%, which has investors questioning if this is right time to ...

Summit Therapeutics (SMMT – Research Report) received a Buy rating and price target from Cantor Fitzgerald analyst Eric Schmidt FCA today.

Corebridge Financial Inc. decreased its holdings in Summit Therapeutics Inc. (NASDAQ:SMMT – Free Report) by 2.3% in the fourth quarter, according to its most recent filing with the Securities and ...

Jaguar Land Rover Automotive, one of Britain's biggest carmakers, said Saturday that the pause would occur this month.

SMMT stock opened at $19.75 on Friday. The company has a market cap of $14.57 billion, a price-to-earnings ratio of -70.53 and a beta of -1.04. The business’s 50-day moving average is $20.28 and ...